EL4 Syngeneic Model Service for Lymphoma

The EL4 syngeneic model service for lymphoma is an immune-competent C57BL/6 platform built on the oldest continuously used chemically induced T-cell lymphoma line in existence, supporting subcutaneous, intradermal, and systemic study formats alongside the field-standard EG7-OVA model antigen system. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated EL4 / EG7-OVA expansion with low-passage banking, implantation into C57BL/6 hosts across validated formats, scheduled caliper and in vivo imaging monitoring, and full lymphoma histopathology with T-cell and costimulation immunophenotyping — all configured around each sponsor’s vaccine, adoptive-therapy, costimulation, or CAR-T hypothesis.

Overview of EL4 Syngeneic Model for Lymphoma

EL4 is a genuine relic of the founding era of tumor immunology: established by Gorer in 1950 from a lymphoma induced in a C57BL/6 mouse by the carcinogen 9,10-dimethyl-1,2-benzanthracene (DMBA), it is the oldest continuously cultured murine lymphoma line and one of the oldest cancer cell lines of any kind. ATCC classifies it as a mouse precursor T-cell lymphoblastic lymphoma/leukemia; the cells carry H-2^b and Thy-1.2, retain the T-cell character that made them indispensable to T-cell biology, and carry the quirks of their era — low-level expression of Gross murine leukemia virus (type G) antigen, documented interleukin production (IL-4 per ECACC, and classic IL-2 production upon stimulation), sensitivity to phytohemagglutinin, and a striking resistance to cortisol and dexamethasone at 10⁻⁴ M that has been exploited in glucocorticoid-response research. A caution documented in the modern literature deserves emphasis: extended passage drives genetic drift and progressively increased immunogenicity in vivo, so low-passage banking is a genuine scientific necessity for this line, not a formality.

Fig 1. EL4-red fluorescent protein (RFP) mouse lymphoma cancer cells were established. (Matsumoto, Takuro, et al., 2015)

In vivo, the parental line is a reliable grower — intradermal implantation of 2 × 10⁶ cells into syngeneic C57BL/6 mice produced tumors in 20 of 20 animals — and it was on this dependability that some of immunology’s most influential experiments were built: the landmark B7 costimulation studies in which EL4 transfected with B7-1 was rejected in 28 of 30 mice while parental tumors grew unchecked, establishing the costimulatory paradigm that underpins modern checkpoint biology. The line’s most consequential derivative is EG7-OVA — EL4 transfected with a complete chicken ovalbumin cDNA — which became the single most widely used model antigen system in cancer immunology, powering DNA- and viral-vector vaccine studies, OT-1 adoptive T-cell therapy experiments, radiation-plus-Th1 cell therapy work, and nanoparticle-engineered cell platforms; published protocols span 2 × 10⁵ to 4 × 10⁶ cells depending on format, with tumors measurable within one to two weeks. Gene-humanized derivatives now extend the platform into CAR-T territory — B-hBCMA-luc EL4, engineered with a chimeric human/mouse BCMA and luciferase, is a documented validation substrate for BCMA-directed cell therapies. Seventy-five years after its derivation, EL4 remains where T-cell lymphoma immunotherapy ideas are first tested.

Cell Line Information: EL4

The table below consolidates the key biological, cultural, and modeling characteristics of the EL4 line and its EG7-OVA and humanized-target derivatives.

Our Services

A line this venerable is only as good as the passage discipline behind it, and Alfa Cytology runs EL4 accordingly: low-passage authenticated banks with documented immunogenicity controls, validated implantation formats for parental and EG7-OVA arms, scheduled caliper and in vivo imaging monitoring, and endpoint pathology tuned to T-cell lymphoma — all under one accountable preclinical operation.

Workflow of EL4 Syngeneic Model Construction

Construction follows the published methodologies for the platform’s deployment formats: EL4 or EG7-OVA cells are expanded under authenticated low-passage conditions, implanted intradermally or subcutaneously into C57BL/6 mice, grown to a standardized baseline, randomized, treated, and analyzed with antigen-specific and histopathological endpoints. The workflow comprises the following stages.

1. Cell authentication and banking: EL4 or EG7-OVA cells are identity-verified, confirmed mycoplasma-negative, documented for low passage number, and re-checked for antigen expression (OVA for EG7 arms), then expanded into working banks under standardized DMEM or RPMI-1640 culture conditions.
2. Cell harvest and formulation: Log-phase cultures are counted and viability-checked, then resuspended at the study-specified dose of approximately 2 × 10⁵ to 4 × 10⁶ cells in 100 – 200 μL of PBS or a Matrigel-supported suspension per the validated format.
3. Anesthesia and implantation: C57BL/6 mice are anesthetized with isoflurane; cells are implanted intradermally or subcutaneously into the flank, with contralateral EL4/EG7-OVA designs used where antigen-specificity controls are required.
4. Establishment monitoring and randomization: Tumors are measured by caliper from first palpability (typically 7–14 days); luciferase-arm studies include in vivo imaging sessions; animals are randomized once tumors reach protocol-specified baselines.
5. Treatment administration: Experimental arms — vaccines, adoptive OT-1 or transgenic T-cell transfer, checkpoint and costimulation reagents, radiation fractions, CAR-T against humanized targets, and combinations — proceed per study design with body-weight and toxicity monitoring.
6. Antigen-specific immune monitoring: Draining-lymph-node, splenic, and tumor-infiltrating populations are sampled on a study-defined schedule for OVA-tetramer⁺ CD8⁺ T-cell quantification, cytotoxicity assays against EL4 versus EG7 targets, and cytokine profiling by ELISPOT and intracellular staining.
7. Endpoint and histopathological analysis: Endpoints integrate tumor-growth inhibition and survival with histopathology (H&E confirming T-lymphoblastic morphology, plus CD3, CD8, Ki67, and marker-specific immunohistochemistry), ex vivo antigen-specificity confirmation in reporter arms, and terminal immune-context profiling.

Fig 2. EL4 Syngeneic Model construction workflow.

Case Study-EL4 Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the EL4 platform spanning vaccine platform benchmarking with EG7-OVA, adoptive T-cell therapy evaluation, and costimulation-mechanism studies across validated implantation formats. In these studies, implanted EL4 tumors were monitored through scheduled caliper and in vivo imaging measurements, treated per randomized regimens, and characterized at endpoint by histopathology with antigen-specific immune monitoring. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology pairs historical-line operational discipline with antigen-system expertise, so every EL4 study is executed with passage-controlled material, validated EG7-OVA workflows, and reporting that reflects the platform’s immunological heritage.

• Focused experience with C57BL/6 T-cell lymphoma models, including EG7-OVA antigen-system workflows and contralateral specificity designs.
• A single coordinated team managing cell banking, implantation, adoptive-transfer logistics, in vivo imaging, and endpoint pathology under one quality framework.
• Low-passage banking with documented immunogenicity control reflecting the line’s known drift behavior.
• Endpoint panels pairing T-lymphoblastic histology with CD3/CD8/Ki67 immunohistochemistry and OVA-tetramer immune monitoring.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your lymphoma program needs the field’s oldest T-cell platform — with the EG7-OVA antigen system, OT-1-ready workflows, and humanized-target derivatives — Alfa Cytology is ready to build the study around your construct. Reach out to us with your regimen and endpoint requirements, or contact us today for a customized proposal and quotation for the EL4 syngeneic model service.

For research use only. Not intended for any clinical use.